Lincoln Pharmaceuticals (531633) Q1 24/25 earnings summary

Executive summary

• Consolidated revenue from operations for Q1 FY25 was ₹14,728.18 lakhs, up from ₹13,561.95 lakhs year-over-year and ₹14,249.30 lakhs sequentially.

• Net profit for the quarter was ₹2,367.17 lakhs, compared to ₹1,901.34 lakhs in Q1 FY24 and ₹1,859.70 lakhs in Q4 FY24.

• Financial results were reviewed by the audit committee and approved by the board on August 8, 2024.

Financial highlights

• Total income for Q1 FY25 was ₹15,769.10 lakhs, up from ₹14,331.03 lakhs year-over-year.

• Total expenses for Q1 FY25 were ₹12,821.31 lakhs, compared to ₹11,786.37 lakhs in Q1 FY24.

• Profit before tax for Q1 FY25 was ₹2,947.79 lakhs, up from ₹2,544.66 lakhs in Q1 FY24.

• Earnings per share (EPS) for Q1 FY25 was ₹11.82, compared to ₹9.49 in Q1 FY24.

Outlook and guidance

• The company continues to operate in a single business segment: Pharmaceutical Business.